Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144


The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma.

Rothe A, Jachimowicz RD, Borchmann S, Madlener M, Keßler J, Reiners KS, Sauer M, Hansen HP, Ullrich RT, Chatterjee S, Borchmann P, Yazaki P, Koslowsky TC, Engert A, Heukamp LC, Hallek M, von Strandmann EP.

Int J Cancer. 2014 Jun 15;134(12):2829-40. doi: 10.1002/ijc.28609.


Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma.

Jachimowicz RD, Fracasso G, Yazaki PJ, Power BE, Borchmann P, Engert A, Hansen HP, Reiners KS, Marie M, von Strandmann EP, Rothe A.

Mol Cancer Ther. 2011 Jun;10(6):1036-45. doi: 10.1158/1535-7163.MCT-10-1093.


A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo.

von Strandmann EP, Hansen HP, Reiners KS, Schnell R, Borchmann P, Merkert S, Simhadri VR, Draube A, Reiser M, Purr I, Hallek M, Engert A.

Blood. 2006 Mar 1;107(5):1955-62.


Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.

Zhang T, Sentman CL.

Cancer Res. 2011 Mar 15;71(6):2066-76. doi: 10.1158/0008-5472.CAN-10-3200.


A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma.

Wang T, Sun F, Xie W, Tang M, He H, Jia X, Tian X, Wang M, Zhang J.

Cancer Lett. 2016 Mar 28;372(2):166-78. doi: 10.1016/j.canlet.2016.01.001.


The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells.

Zhu S, Denman CJ, Cobanoglu ZS, Kiany S, Lau CC, Gottschalk SM, Hughes DP, Kleinerman ES, Lee DA.

Pharm Res. 2015 Mar;32(3):779-92. doi: 10.1007/s11095-013-1231-0.


Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma.

Zhang Z, Su T, He L, Wang H, Ji G, Liu X, Zhang Y, Dong G.

Tohoku J Exp Med. 2012;226(1):59-68. doi: 10.6120/tjem.226.59.


Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.

Wu L, Parton A, Lu L, Adams M, Schafer P, Bartlett JB.

Cancer Immunol Immunother. 2011 Jan;60(1):61-73. doi: 10.1007/s00262-010-0919-9.


Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.

Shi L, Lin H, Li G, Sun Y, Shen J, Xu J, Lin C, Yeh S, Cai X, Chang C.

Cancer Lett. 2016 Apr 1;373(1):45-56. doi: 10.1016/j.canlet.2016.01.017.


Treatment with a fusion protein of the extracellular domains of NKG2D to IL-15 retards colon cancer growth in mice.

Xia Y, Chen B, Shao X, Xiao W, Qian L, Ding Y, Ji M, Gong W.

J Immunother. 2014 Jun;37(5):257-66. doi: 10.1097/CJI.0000000000000033.


Expansion of NK cells by engineered K562 cells co-expressing 4-1BBL and mMICA, combined with soluble IL-21.

Jiang B, Wu X, Li XN, Yang X, Zhou Y, Yan H, Wei AH, Yan W.

Cell Immunol. 2014 Jul;290(1):10-20. doi: 10.1016/j.cellimm.2014.04.011.


Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.

Textor S, Fiegler N, Arnold A, Porgador A, Hofmann TG, Cerwenka A.

Cancer Res. 2011 Sep 15;71(18):5998-6009. doi: 10.1158/0008-5472.CAN-10-3211.


Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.

Doubrovina ES, Doubrovin MM, Vider E, Sisson RB, O'Reilly RJ, Dupont B, Vyas YM.

J Immunol. 2003 Dec 15;171(12):6891-9.


Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D.

Heinemann A, Zhao F, Pechlivanis S, Eberle J, Steinle A, Diederichs S, Schadendorf D, Paschen A.

Cancer Res. 2012 Jan 15;72(2):460-71. doi: 10.1158/0008-5472.CAN-11-1977.


Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.

Kuroki M, Hachimine K, Huang J, Shibaguchi H, Kinugasa T, Maekawa S, Kuroki M.

Anticancer Res. 2005 Nov-Dec;25(6A):3725-32. Review.


NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.

Spear P, Barber A, Rynda-Apple A, Sentman CL.

Immunol Cell Biol. 2013 Jul;91(6):435-40. doi: 10.1038/icb.2013.17.


Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.

Schwinn N, Vokhminova D, Sucker A, Textor S, Striegel S, Moll I, Nausch N, Tuettenberg J, Steinle A, Cerwenka A, Schadendorf D, Paschen A.

Int J Cancer. 2009 Apr 1;124(7):1594-604. doi: 10.1002/ijc.24098.


Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2/5/6 and chemoattract NK cells.

Wennerberg E, Pfefferle A, Ekblad L, Yoshimoto Y, Kremer V, Kaminskyy VO, Juhlin CC, Höög A, Bodin I, Svjatoha V, Larsson C, Zedenius J, Wennerberg J, Lundqvist A.

Clin Cancer Res. 2014 Nov 15;20(22):5733-44. doi: 10.1158/1078-0432.CCR-14-0291.


Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity.

Kellner C, Hallack D, Glorius P, Staudinger M, Mohseni Nodehi S, de Weers M, van de Winkel JG, Parren PW, Stauch M, Valerius T, Repp R, Humpe A, Gramatzki M, Peipp M.

Leukemia. 2012 Apr;26(4):830-4. doi: 10.1038/leu.2011.288. No abstract available.

Items per page

Supplemental Content

Support Center